FDA OKs First Biodegradable Implant to Lower IOP

by Medscape • 2020/03/06 • 0 Comments

Bimatoprost implant (Durysta) delivers 10 µg of the prostaglandin analog and is an alternative to daily topical eye drops in patients with open-angle glaucoma or ocular hypertension.
FDA Approvals

Full Story →

← Cyclophotocoagulation with trabecular meshwork bypass MIGS may lead to sustained IOP reduction

Two retinal imaging modalities cannot be interchanged when evaluating vision-threatening condition →

Post navigation